As shown in Table 1, differences were not statistically significant between APOBEC3G high and APOBEC3G low AML patients according to gender, race, age, white blood cell (WBC) count, BM/PB blast, cytogenetic risks, and FLT3 and CEBPA mutations (p > 0.05 for all). This evidence concerns the gene FLT3 and acute myeloid leukemia.